Abstract
HEART transplantation remains standard surgical therapy for select patients with end-stage heart failure. Due to longer waiting list times, an increasing number of potential recipients require mechanical circulatory support as a bridge to transplantation. However, placement of mechanical cardiac assist devices often leads to the use of multiple blood products and results in high levels of preformed cytotoxic alloantibodies to MHC class I antigen. We hypothesized that the use of intravenous immune gamma globulin (IVIG) would decrease the level of preformed cytotoxic alloantibodies. We report the use of IVIG in these highly sensitized patients awaiting heart transplantation on mechanical circulatory support.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
